IBDEI2N6 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44337,1,4,0)
 ;;=4^C92.A0
 ;;^UTILITY(U,$J,358.3,44337,2)
 ;;=^5001813
 ;;^UTILITY(U,$J,358.3,44338,0)
 ;;=C92.51^^200^2228^13
 ;;^UTILITY(U,$J,358.3,44338,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44338,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,44338,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,44338,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,44339,0)
 ;;=C92.50^^200^2228^14
 ;;^UTILITY(U,$J,358.3,44339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44339,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,44339,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,44339,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,44340,0)
 ;;=C94.40^^200^2228^17
 ;;^UTILITY(U,$J,358.3,44340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44340,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,44340,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,44340,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,44341,0)
 ;;=C94.42^^200^2228^15
 ;;^UTILITY(U,$J,358.3,44341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44341,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,44341,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,44341,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,44342,0)
 ;;=C94.41^^200^2228^16
 ;;^UTILITY(U,$J,358.3,44342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44342,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,44342,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,44342,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,44343,0)
 ;;=D62.^^200^2228^18
 ;;^UTILITY(U,$J,358.3,44343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44343,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,44343,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,44343,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,44344,0)
 ;;=C92.41^^200^2228^19
 ;;^UTILITY(U,$J,358.3,44344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44344,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,44344,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,44344,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,44345,0)
 ;;=C92.40^^200^2228^20
 ;;^UTILITY(U,$J,358.3,44345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44345,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,44345,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,44345,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,44346,0)
 ;;=D56.0^^200^2228^21
 ;;^UTILITY(U,$J,358.3,44346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44346,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,44346,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,44346,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,44347,0)
 ;;=D63.1^^200^2228^23
 ;;^UTILITY(U,$J,358.3,44347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44347,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,44347,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,44347,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,44348,0)
 ;;=D63.0^^200^2228^24
 ;;^UTILITY(U,$J,358.3,44348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44348,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,44348,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,44348,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,44349,0)
 ;;=D63.8^^200^2228^22
 ;;^UTILITY(U,$J,358.3,44349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44349,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,44349,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,44349,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,44350,0)
 ;;=C22.3^^200^2228^25
 ;;^UTILITY(U,$J,358.3,44350,1,0)
 ;;=^358.31IA^4^2
